The CXCR4 antagonist plerixafor is a potential therapy for myelokathexis, WHIM syndrome. - Wikidata - wikimedia - TriplyDB

The CXCR4 antagonist plerixafor is a potential therapy for myelokathexis, WHIM syndrome.

The CXCR4 antagonist plerixafor is a potential therapy for myelokathexis, WHIM syndrome.

http://www.wikidata.org/entity/Q34207531

about

Primary immunodeficiency update: Part II. Syndromes associated with mucocutaneous candidiasis and noninfectious cutaneous manifestations Targeting the molecular and cellular interactions of the bone marrow niche in immunologic disease Neutrophil mobilization via plerixafor-mediated CXCR4 inhibition arises from lung demargination and blockade of neutrophil homing to the bone marrow A phase 1 clinical trial of long-term, low-dose treatment of WHIM syndrome with the CXCR4 antagonist plerixafor Chromothriptic cure of WHIM syndrome.IL-1α and complement cooperate in triggering local neutrophilic inflammation in response to adenovirus and eliminating virus-containing cells Filamin A interaction with the CXCR4 third intracellular loop regulates endocytosis and signaling of WT and WHIM-like receptors WHIM syndrome caused by a single amino acid substitution in the carboxy-tail of chemokine receptor CXCR4.Chromothriptic cure of WHIM syndrome: Implications for bone marrow transplantation Neutrophil reverse migration becomes transparent with zebrafish.Tetralogy of fallot is an uncommon manifestation of warts, hypogammaglobulinemia, infections, and myelokathexis syndrome Description and outcome of a cohort of 8 patients with WHIM syndrome from the French Severe Chronic Neutropenia Registry Neutropenia in primary immunodeficiency G-CSF maintains controlled neutrophil mobilization during acute inflammation by negatively regulating CXCR2 signaling.International Union of Basic and Clinical Pharmacology. [corrected]. LXXXIX. Update on the extended family of chemokine receptors and introducing a new nomenclature for atypical chemokine receptors.Genetics on a WHIM.Defects of leukocyte migration in primary immunodeficiencies.How we diagnose and treat neutropenia in adults.Targeted strategies directed at the molecular defect: Toward precision medicine for select primary immunodeficiency disorders.Inhibition of CXCR4-CXCL12 chemotaxis in melanoma by AMD11070.Is the post-transplantation treatment with AMD beneficial?Co-targeting aurora kinase with PD-L1 and PI3K abrogates immune checkpoint mediated proliferation in peripheral T-cell lymphoma: a novel therapeutic strategy.Pathogenesis, diagnosis and therapeutic strategies in WHIM syndrome immunodeficiency.Multisystem multitasking by CXCL12 and its receptors CXCR4 and ACKR3.Mechanisms of Sustained Neutrophilia in Patient WHIM-09, Cured of WHIM Syndrome by Chromothripsis.From clinical observations and molecular dissection to novel therapeutic strategies for primary immunodeficiency disorders.Cxcr4-haploinsufficient bone marrow transplantation corrects leukopenia in an unconditioned WHIM syndrome model.

P2860

Q26830870-E5676B3C-6089-4C19-912C-8AB5267A51A4 Q26865498-B7223A32-947E-4916-8338-D2F51DB5F579 Q30552565-01481259-5C10-4903-8064-C79AAEB58247 Q34403975-78A14994-2B96-42FB-98FC-F857B4A0D68A Q35085186-9CFCC53E-43FA-428B-A07F-F7094AFECE5D Q35126751-64CE6CEF-07CC-42A1-A4AC-CD952271C042 Q35140322-D2ADEB47-AE29-4865-947A-C5F4A2C722EC Q36079791-6DCCC387-9842-44B6-BCDA-6BBF2027C48E Q36106592-17E7883D-2AA3-46A6-A9E9-0C7DF9B23A9E Q36107308-8F57F80B-5986-4692-96E6-42758C032A86 Q36280139-2EFD8D69-36F3-424D-9C0D-0750D5D0D0EF Q36649222-C327FD58-E775-4E51-BDDC-6D7A749FF97D Q37210757-C0DB9F95-5204-4673-AF68-E86A6AC0F5E8 Q37272113-C8035F12-4CC3-46B5-895C-B73A0110CA2E Q37432097-A0D2189D-D843-424F-BFFE-915142CA350B Q37653020-863A93A4-34F6-4D56-BA81-7D9D0B0C8345 Q38102968-4E646AFF-AEF2-4440-91B3-8CD2184F72AC Q38700289-4D2B6C7D-D975-4D24-AFD6-48555EC1D54B Q39166973-D6330B27-215E-430C-845D-68B48F994C76 Q39174058-66179558-669C-484F-A938-01419557FF99 Q42139478-2D543D89-B184-4E12-9556-5702571DE35E Q47147843-BA920E34-9304-4E36-96F7-1AB38BB6FC10 Q48624133-857CE97F-7338-41EE-B7DA-9392E1176020 Q49343068-66B7B5F7-A4E1-4F51-B062-EAB0393A6C60 Q49606275-627723F2-64EB-48B3-B9F6-9782AF8161F1 Q53061634-B7910AD4-142B-48EF-9152-58E6A46B017D Q54223980-939970B7-8B18-4FAA-A839-8119C22338F7

P2860

The CXCR4 antagonist plerixafor is a potential therapy for myelokathexis, WHIM syndrome.

http://www.wikidata.org/entity/Q34207531

description

2011 nî lūn-bûn

@nan

2011 թուականի Օգոստոսին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի օգոստոսին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

name

The CXCR4 antagonist plerixafor is a potential therapy for myelokathexis, WHIM syndrome.

@ast

The CXCR4 antagonist plerixafor is a potential therapy for myelokathexis, WHIM syndrome.

@en

The CXCR4 antagonist plerixafor is a potential therapy for myelokathexis, WHIM syndrome.

@nl

type

label

The CXCR4 antagonist plerixafor is a potential therapy for myelokathexis, WHIM syndrome.

@ast

The CXCR4 antagonist plerixafor is a potential therapy for myelokathexis, WHIM syndrome.

@en

The CXCR4 antagonist plerixafor is a potential therapy for myelokathexis, WHIM syndrome.

@nl

prefLabel

The CXCR4 antagonist plerixafor is a potential therapy for myelokathexis, WHIM syndrome.

@ast

The CXCR4 antagonist plerixafor is a potential therapy for myelokathexis, WHIM syndrome.

@en

The CXCR4 antagonist plerixafor is a potential therapy for myelokathexis, WHIM syndrome.

@nl

P1433

Q34207531-75366B4C-7D88-48F0-A28E-B372BEB35177

P1476

Q34207531-B72D594F-4854-45A3-AE59-D093AAFB26DC

P2093

Q34207531-5AD93E69-483E-47E2-95CA-27EF13DDA667

Q34207531-62B26B95-5A78-4D3C-B7B4-9E37F6453418

Q34207531-744B9593-B099-41A7-B7B2-C77FD9473AF6

Q34207531-7A7A5EA1-DDAE-40BF-B41F-5D72CD23A4DC

Q34207531-8F92807F-A045-4574-B44E-2CB905ED0E10

Q34207531-B993E033-F6D2-486F-9311-43A64653DD62

Q34207531-E5EFAF9D-A5BB-444F-A5F7-F93DD3FB8A77

Q34207531-F08E4C3E-476B-40C6-8E41-57CA2B674236

P2860

Q34207531-182C1769-6570-4265-AADF-EB3C77B0CE96

Q34207531-4A98F365-17C0-4F47-9BD9-5835182265FD

Q34207531-4DB048A9-EC47-4EFF-BE57-B9F1734353DF

Q34207531-579C0A47-8AE3-4427-AD2D-D3CC03AD018C

Q34207531-87287648-94C5-4C9A-A629-7431DEC77003

Q34207531-A8AD12B9-072F-4A08-B44D-872F0CD5BDBB

P304

Q34207531-0150D548-B5BB-45B6-84B9-787A54DEFCC2

P31

Q34207531-57E96005-845E-42E2-8125-2D1B1477DE4C

P356

Q34207531-FBA3B839-F6E5-45B1-AA9A-F565DCF8B107

P407

Q34207531-A5C17C47-4F80-45B0-9992-E8A8922D1598

P433

Q34207531-69EFE652-C215-492B-B4CF-945A8D3FA07B

P478

Q34207531-3726878A-F7BA-44EC-94D9-0B474B9DFAB2

P577

Q34207531-12ABBF6F-C9D4-4183-9F75-74411FA95891

P5875

Q34207531-E2043CFE-343A-4C31-9CC7-2396A7D26BE1

P698

Q34207531-46154AAA-D5B9-43F5-930C-CAF187376797

P932

Q34207531-36F8F225-AD4A-459A-A5CC-C8F5A64A911B

P356

BLOOD-2011-06-360586

P1433

P1476

The CXCR4 antagonist plerixafor is a potential therapy for myelokathexis, WHIM syndrome.

@en

P2093

Andrew Aprikyan

http://www.w3.org/2001/XMLSchema#string

Audrey Anna Bolyard

http://www.w3.org/2001/XMLSchema#string

Brent Wood

http://www.w3.org/2001/XMLSchema#string

David C Dale

http://www.w3.org/2001/XMLSchema#string

Ernest C Westrup

http://www.w3.org/2001/XMLSchema#string

Frank J Hsu

http://www.w3.org/2001/XMLSchema#string

Merideth L Kelley

http://www.w3.org/2001/XMLSchema#string

Vahagn Makaryan

http://www.w3.org/2001/XMLSchema#string

P2860

AMD3100 is a potent antagonist at CXCR4(R334X) , a hyperfunctional mutant chemokine receptor and cause of WHIM syndrome

Mutations in the chemokine receptor gene CXCR4 are associated with WHIM syndrome, a combined immunodeficiency disease.

Enhanced function with decreased internalization of carboxy-terminus truncated CXCR4 responsible for WHIM syndrome.

Chemokine receptor inhibition by AMD3100 is strictly confined to CXCR4.

Plerixafor and G-CSF versus placebo and G-CSF to mobilize hematopoietic stem cells for autologous stem cell transplantation in patients with multiple myeloma.

A pharmacokinetic-pharmacodynamic model for the mobilization of CD34+ hematopoietic progenitor cells by AMD3100.

P304

4963-4966

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1182/BLOOD-2011-06-360586

http://www.w3.org/2001/XMLSchema#string

P407

P433

18

http://www.w3.org/2001/XMLSchema#string

P478

118

http://www.w3.org/2001/XMLSchema#string

P577

2011-08-11T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

51566015

http://www.w3.org/2001/XMLSchema#string

P698

21835955

http://www.w3.org/2001/XMLSchema#string

P932

3673761

http://www.w3.org/2001/XMLSchema#string